Merck KGaA Highlights First In Class Five For 2025 Market Boom
Executive Summary
From BTK inhibitors in multiple sclerosis to candidates aiding cancer cell death, Merck KGaA is focusing on its first-in-class pipeline which it expects to make a significant impact from 2025.